Olmesartan and intestinal adverse effects in the ROADMAP study.

Abstract

To the Editor: We read the article by Rubio-Tapia and colleagues with great interest. In this article, the authors describe the occurrence of severe spruelike enteropathy in 22 patients, all of whom received olmesartan (predominantly 40 mg/d) besides other drugs. All patients had longlasting diarrhea (3-53 months) and weight loss (2.5-50 kg). Many patients… (More)
DOI: 10.1016/j.mayocp.2012.10.005

Topics

Cite this paper

@article{Menne2012OlmesartanAI, title={Olmesartan and intestinal adverse effects in the ROADMAP study.}, author={Jan Menne and Hermann Haller}, journal={Mayo Clinic proceedings}, year={2012}, volume={87 12}, pages={1230-1; author reply 1232} }